June PCE, Bristol Myers Squibb earnings: What to watch Friday
Asking for a Trend Host Josh Lipton breaks down what to watch on Friday, July 26th. Personal Consumption Expenditures (PCE)…
54,240€
-0,75%
Echtzeit-Aktienkurs Bristol-Myers Squibb Co.
Bid:
Ask:
Nachrichten zur Bristol-Myers Squibb Co. Aktie
Global Musculoskeletal Market Size is Expected To Hold a Significant Share By 2033 | CAGR of 6.2%
The Market Size is Growing at a Substantial CAGR of 6.2% from 2023 to 2033 and the Worldwide Musculoskeletal Market…
NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program
Bristol Myers Squibb Company, et al. v. Xavier Becerra, et al. Bristol Myers Squibb Company, et al. v. Xavier Becerra,…
Bristol-Myers Squibb - Investors Are Too Long-Term Focused (NYSE:BMY)
Bristol-Myers Squibb faces challenges with patent expirations, but has long-term shareholder return potential. Read why BMY stock is a good investment.…
Bristol-Myers Squibb Is A Bargain Now
…
Is Bristol-Myers Squibbs Rich Dividend Yield Worth The Patent Cliff Correction Risk?
…
Bristol-Myers Squibb: Seriously Undervalued And Poised For An Inflection
…
Erste Schätzungen: Bristol-Myers Squibb vermeldet Zahlen zum jüngsten Quartal
Bristol-Myers Squibb wird voraussichtlich am 26.07.2024 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 30.06.2024 – vorstellen.Die Schätzungen…
Bristol-Myers Squibb: Time To Double Down
…
Is Bristol Myers Squibb Stock a Buy?
Does Bristol Myers have the potential to be a market-beating stock?…
Is Bristol Myers Squibb Stock a Buy? @themotleyfool #stocks $BMY
Does Bristol Myers have the potential to be a market-beating stock?…
Global Lenalidomide Drug Market Size To Worth USD 21.47 Billion By 2033 | CAGR Of 5.69%
The Global Lenalidomide Drug Market Size was Valued at USD 12.34 Billion in 2023 and the Worldwide Lenalidomide Drug Market…
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
These two pharma stocks are beloved by income investors.…
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
…
OrganoClick appoints Carin Eklund as new CFO
OrganoClick has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClicks finance and economics department…
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least
…
Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least (NYSE:BMY)
Bristol-Myers Squibb still elevated forward P/E indicates its unlikely to see an uptick anytime this year. Click here to read…
Evotec: Gute Nachrichten
Evotec verkündet einen Fortschritt in der Partnerschaft mit Bristol Myers Squibb.…
Evotec: Ein wichtiger Fortschritt innerhalb der Neurologie-Partnerschaft mit Bristol-Myers Squibb - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Evotec-Aktienanalyse von "Der Aktionär":
Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt die Aktie der Evotec SE (ISIN: DE0005664809,…
EQS-News: Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt (deutsch)
Evotec gibt Fortschritt in Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec gibt Fortschritt in Neurologie-Partnerschaft mit…
Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis)
…
Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference
…
Bristol Myers Squibb wins antitrust case against insurers regarding generics
…
Analyst Report: Bristol-Myers Squibb Co.
…
Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss
…
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974 (“ERISA”) (Brower Piven Release)
BALTIMORE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Lawsuits have been filed alleging that a number of large…
Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
…
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult…
Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript
…
Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript)
…
Biotech Reveals More From The Study That Boosted Shares 83%
The company is hoping to take on Bristol Myers Squibbs Camzyos, a treatment for obstructive HCM.…
Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma
The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake,…
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock.…
If Youd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Heres How Much Youd Have Today
The answer isnt great, but theres still reason to like Bristol Myers Squibb.…
Bristol-Myers Squibb: A Lost Decade?
…
Neue Analysteneinschätzung - Carbon Done Right Developments, Bristol Myers Squibb, Deutsche Lufthansa Aktie
Negative Wirtschaftsdaten aus den USA belasteten zuletzt die Indizes. Das abschwächende Wirtschaftswachstum in den USA, wie auch die anhaltende Inflation…
Pfizer: Doppelschlag vor den Zahlen – das wird erwartet
Mit Eli Lilly und Merck & Co haben bereits zwei große amerikanische Pharma-Konzerne überzeugende Ergebnisse vorgelegt. Bristol-Myers Squibb hingegen patzte…
Bristol Myers Squibb: Tough Times Continue
…
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality…
Bristol-Myers Squibb: Pharmagigant will die Kosten massiv drücken - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…
Bristol-Myers Squibb: Aktie im freien Fall – das steckt dahinter
Bristol Myers Squibb enttäuschte mit den Zahlen für das erste Quartal.…
Bristol Myers Squibb: Aktie bricht nach Zahlen massiv ein – jetzt günstig einsteigen?
Der amerikanische Pharma-Konzern Bristol Myers Squibb hat mit seinen Zahlen zum ersten Quartal für Ernüchterung gesorgt. Nach der Bekanntgabe der…
Bristol Myers Squibb: Aktie bricht nach Zahlen massiv ein – jetzt günstig einsteigen?
Der amerikanische Pharma-Konzern Bristol Myers Squibb hat mit seinen Zahlen zum ersten Quartal für Ernüchterung gesorgt. Nach der Bekanntgabe der…
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
…
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
BMY earnings call for the period ending March 31, 2024.…
Is Bristol Myers Squibb Stock a Millionaire Maker?
Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors.…
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda…